Fig. 1
From: Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy
Wnt secretion inhibitors reduce bone volume and bone mineral density in dose-dependent manner: C57/BL6 mice were treated daily for 4 weeks with vehicle or the indicated oral doses of ETC-159 or LGK974. Femurs were then collected and analyzed by µCT. a Schematic of regions analyzed by µCT. µCT parameters assessed were b, c trabecular bone volume fraction (bone volume (BV)/tissue volume (TV)), d bone mineral density (BMD), e trabecular number, f trabecular separation, and g trabecular thickness. h Representative cross-sectional images from the cortical region. µCT parameters assessed were i average cross-sectional thickness, j tissue mineral density (TMD), and k cortical area fraction (CAF = bone area (B.Ar)/tissue area (T.Ar)). Data are presented as mean ± SD, (n = 6 mice/group). The significance of changes compared to the Vehicle group is indicated. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
